At the American Academy of Neurology meeting, researchers gave final results of the phase III PRECISE trial of glatiramer acetate (Copaxone), which delayed the onset of clinically confirmed multiple sclerosis by more than a year in patients with early signs of the disease.

For more information visit:
American Academy of Neurology

Sponsored by The Doctor’s Channel